NCCN SCLC guidelines add LEMS testing and amifampridine (FIRDAPSE) treatment recommendation

CATALYST PHARMACEUTICALS, INC.

NCCN guidelines for SCLC updated to recommend VGCC antibody testing for LEMS diagnosis.
Amifampridine (FIRDAPSE) added as a supportive care treatment option for LEMS in SCLC.
Approximately 50% of LEMS cases are cancer-associated, most commonly with SCLC.
Catalyst internal analysis suggests 90% of LEMS in SCLC patients may be undiagnosed.
Guideline inclusion could increase clinical awareness and drive adoption of VGCC testing and amifampridine use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.